This article is more than 5 years old. Information may no longer be current.

Condoliase may prove effective in treating lumbar disc herniations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

COPENHAGEN, Denmark — Condoliase, an enzyme that degrades glycosaminoglycans, was well-tolerated by patients who received it as a treatment for lumbar disc herniations, according to a speaker here.

Kazuhiro Chiba, MD, said condoliase reduces compression on nerves and can be a less-invasive curative treatment for patients with lumbar disc herniations.

“Condoliase significantly improved symptoms and signs, physical function and quality of life scores in patients with lumbar disc herniations,” Chiba said at the EuroSpine Annual Meeting.

The multicenter, double-blind, randomized, placebo-controlled trial included 163 patients with lumbar disc herniations. Eighty-two patients received injections of 1 mL of condoliase dissolved in 1 mL of saline and 81 patients received placebo injections, he said.

Chiba noted the condoliase group experienced significantly better improvement in VAS scores for leg pain from baseline to 13-week follow-up (P = .001) compared with the placebo group. Additionally, imaging confirmed the condoliase group saw a greater volume decrease of the herniated mass than the placebo group.

The most common adverse event in the study was back pain, which was more evident in the condoliase group (36.6%) than the placebo group (33.3%), but most events were rated as mild or moderate, Chiba said. – by Robert Linnehan

Reference: Chiba K, et al. Paper #44. Presented at: EuroSpine Annual Meeting; Sept. 2-4, 2015; Copenhagen, Denmark.

Disclosure: Chiba reports receiving grants/research support from Seikagaku Corporation. He reports being a consultant for the Seikagaku Corporation, Dentsu Sudler & Hennessey Inc. and the General Insurance Rating Organization. He reports receiving royalties from Sumitomo Dainippon Pharma Co., Ltd., Japan Broadcasting Corporation and Medical View C, Ltd. He reports receiving other financial reports from Seikagaku Corporation, Astellas Pharma Inc., and Showa Yakuhin Kako Co., Ltd.